Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.

Gupta S, Fricker FJ, González-Peralta RP, Slayton WB, Schuler PM, Dharnidharka VR.

Pediatr Transplant. 2010 Nov;14(7):896-902. doi: 10.1111/j.1399-3046.2010.01370.x.

PMID:
20642490
2.

Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.

Lee JJ, Lam MS, Rosenberg A.

Ann Pharmacother. 2007 Oct;41(10):1648-59. Epub 2007 Sep 11. Review.

PMID:
17848421
4.

Post-transplant lymphoproliferative disorders following solid-organ transplantation.

Blaes AH, Morrison VA.

Expert Rev Hematol. 2010 Feb;3(1):35-44. doi: 10.1586/ehm.09.76. Review.

PMID:
21082932
5.

Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.

Svoboda J, Kotloff R, Tsai DE.

Transpl Int. 2006 Apr;19(4):259-69. Review.

6.

Posttransplant lymphoproliferative disorder.

Everly MJ, Bloom RD, Tsai DE, Trofe J.

Ann Pharmacother. 2007 Nov;41(11):1850-8. Epub 2007 Oct 16. Review. Erratum in: Ann Pharmacother. 2007 Dec;41(12):2074.

PMID:
17940127
7.
8.

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.

Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA.

Cancer. 2005 Oct 15;104(8):1661-7. Review.

9.

Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.

Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ.

Transpl Int. 2007 Mar;20(3):207-18. Review.

10.

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

Styczynski J, Einsele H, Gil L, Ljungman P.

Transpl Infect Dis. 2009 Oct;11(5):383-92. doi: 10.1111/j.1399-3062.2009.00411.x. Epub 2009 Jun 23. Review.

PMID:
19558376
11.

Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.

Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI.

Curr Oncol Rep. 2010 Nov;12(6):383-94. doi: 10.1007/s11912-010-0132-1. Review.

PMID:
20963522
12.

Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Jagadeesh D, Woda BA, Draper J, Evens AM.

Curr Treat Options Oncol. 2012 Mar;13(1):122-36. doi: 10.1007/s11864-011-0177-x. Review.

PMID:
22241590
13.

[Treatment of post-transplant lymphoproliferative disease with rituximab].

Jiang YJ, Wang X.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):852-6. doi: 10.7534/j.issn.1009-2137.2014.03.052. Review. Chinese.

PMID:
24989308
14.

Low-dose chemotherapy for children with post-transplant lymphoproliferative disease.

Gross TG.

Recent Results Cancer Res. 2002;159:96-103. Review.

PMID:
11785850
15.

Localization of post-transplant lymphoproliferative disorders to the stomach might be associated with favorable outcome: a systematic review.

Khedmat H, Ghamar-Chehreh ME, Amini M, Agah S, Taheri S.

Saudi J Kidney Dis Transpl. 2014 Mar;25(2):353-61. Review.

16.

[Novel uses of rituximab].

Frenzel L.

Rev Prat. 2013 Dec;63(10):1349-53. Review. French.

PMID:
24579323

Supplemental Content

Support Center